Author:
Yamano Tomoki,Yamauchi Shinichi,Igeta Masataka,Takenaka Yuya,Song Jihyung,Kimura Kei,Yasuhara Michiko,Babaya Akihito,Kataoka Kozo,Beppu Naohito,Ikeda Masataka,Tomita Naohiro,Sugihara Kenichi
Abstract
AbstractTumour-Node-Metastasis (TNM) staging of colorectal cancer (CRC) needs further classification for better treatment because of disease heterogeneity. Although molecular classifications which are expensive and laborious are under study, cost and labour efficient subtyping is desirable. We assessed the combinations of preoperative tumour marker (TM) elevation and tumour lymphovascular invasion (LVI) as a solution. We used the pooled data of 7151 colon cancer (CC) patients and 4620 rectal cancer (RC) patients who received curative surgery between 2004 and 2008 in Japan. The best-matched subtyping for predicting relapse-free survival (RFS) was statistically selected using the c-index and Akaike’s information criterion. This subtyping (TM-LVI), which consisted of three categories by TM elevation status and severity of LVI status, was an independent prognostic factor for RFS of CC (stage IIa, IIIb, and IIIc) and RC (stage I, IIa, IIb, IIIa, and IIIb) and also for disease specific survival of CC (stage IIa, IIb, IIIb, and IIIc) and RC (all stage except for IIc). Although TM-LVI classified CRC patients into low and high recurrence risk groups, the application of adjuvant therapy was not accordance with the TM-LVI status. TM-LVI may be a cost and labour efficient subtyping of colorectal cancer for better treatment strategy.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. André, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).
2. Labianca, R. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi64–72 (2013).
3. NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. (NCCN Guidelines) version1. 2019 colon cancer. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
4. NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. (NCCN Guidelines) version1. 2019 rectal cancer. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
5. Iveson, T. J. et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 19, 562–578 (2018).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献